Thursday, January 21, 2021

Rhizen receives USFDA orphan drug designation for cancer drug

The US Food and Drug Administration (USFDA) has granted orphan drug
designation for Tenalisib (RP6530) for the treatment of patients with
peripheral T-cell lymphoma (PTCL), Alembic Pharmaceuticals said in a
BSE filing.

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/rhizen-receives-usfda-orphan-drug-designation-for-cancer-drug/articleshow/80401115.cms

No comments:

Post a Comment